M
Morgane Tardy
Researcher at Université catholique de Louvain
Publications - 3
Citations - 612
Morgane Tardy is an academic researcher from Université catholique de Louvain. The author has contributed to research in topics: Cancer & Proto-oncogene tyrosine-protein kinase Src. The author has an hindex of 2, co-authored 2 publications receiving 452 citations.
Papers
More filters
Journal ArticleDOI
A Mitochondrial Switch Promotes Tumor Metastasis
Paolo E. Porporato,Valéry Payen,Jhudit Pérez-Escuredo,Christophe De Saedeleer,Pierre Danhier,Tamara Copetti,Suveera Dhup,Morgane Tardy,Thibaut Vazeille,Caroline Bouzin,Olivier Feron,Carine Michiels,Bernard Gallez,Pierre Sonveaux +13 more
TL;DR: Two different events, ETC overload and partial ETC inhibition, promote superoxide-dependent tumor cell migration, invasion, clonogenicity, and metastasis, and specific scavenging of mitochondrial superoxide with mitoTEMPO blocked tumor cell Migration and prevented spontaneous tumor metastasis in murine and human tumor models.
Journal ArticleDOI
Lactate Dehydrogenase B Controls Lysosome Activity and Autophagy in Cancer
Lucie Brisson,Piotr Bański,Martina Sboarina,Coralie Dethier,Pierre Danhier,Marie Joséphine Fontenille,Vincent F. Van Hée,Thibaut Vazeille,Morgane Tardy,Jorge Falces,Caroline Bouzin,Paolo E. Porporato,Raphaël Frédérick,Carine Michiels,Tamara Copetti,Pierre Sonveaux +15 more
TL;DR: It is reported that lactate sustains autophagy in cancer, and LDHB activity is necessary for basalAutophagy and cancer cell proliferation not only in oxidative cancer cells but also in glycolytic cancer cells.
Journal ArticleDOI
Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction.
Raphael Le Biannic,Romain Magnez,Frederique Klupsch,Natascha Leleu-Chavain,Bryan Thiroux,Morgane Tardy,H El Bouazzati,Xavier Dezitter,Nicolas Renault,Gérard Vergoten,Christian Bailly,Bruno Quesnel,Xavier Thuru,Régis Millet +13 more
TL;DR: The microwave-assisted synthesis and the characterization of an innovative series of synthetic compounds endowed with nanomolar activity against PD-L1 offers novel perspectives to design PD- L1-targeting agents, potentially useful to combat cancer and other pathologies implicating the PD-1/PD-L 1 checkpoint.